CURE Pharmaceutical, a disruptive drug delivery technology and pharmaceutical cannabinoid molecule company, has formed a partnership with a pharmaceutical distribution company to deliver a generic erectile dysfunction (ED) drug on its patented, multilayer oral thin film (OTF), CureFilm, into the Asian market.
Asia
“This OTF erectile dysfunction product is a testament to CURE’s ability to take generic drugs and reformulate them onto OTF products, which for this indication, offers multiple benefits including discreet administration and faster onset,” said CEO of CURE Pharmaceutical, Rob Davidson. “We are excited to be teaming up with leading distribution partners like this that will distribute our OTF ED drug throughout Asia, which is expected to see growth for ED drugs and an extremely lucrative market for generic drugs.”
The patented, multilayer OTF, CureFilm, is designed to be administered orally, without the need for water. By delivering the medication to the tongue, cheek or sublingual regions of the mouth, it can access the blood stream enterically, buccally or sublingually. It has been developed to improve the pharmacokinetic profile and the overall therapeutic index of an API.
The reformulated generic ED drug will be targeted for distribution in China, Hong Kong, Japan, Korea, Singapore, the Philippines, Taiwan, Vietnam and Thailand.